Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • pancreatic cancer

    - PMLiVE

    Mainz Biomed reports on blood-based screening test for pancreatic cancer

    The study demonstrated strong clinical accuracy in differentiating pancreatic cancer patients from control subjects

    - PMLiVE

    New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

    The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

    - PMLiVE

    Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

    Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

    - PMLiVE

    Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

    Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

    - PMLiVE

    Study shows blood test could be as accurate as lumbar punctures for detecting Alzheimer’s

    ALZpath successfully detected levels of a form of the hallmark tau protein in the blood

    - PMLiVE

    FDA grants fast track designation to Candel’s immunotherapy in pancreatic cancer

    The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

    - PMLiVE

    New blood test to reduce heart attacks and death rates in A&E heart patients

    The test could improve diagnosis for one in five patients with a heart muscle injury

    - PMLiVE

    Candel announces promising results for immunotherapy candidate in pancreatic cancer

    Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

    - PMLiVE

    Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer

    More than 90% of patients with locally advanced disease are not eligible for surgery

    - PMLiVE

    Researchers at ICR London discover new nutrient source for cancer growth

    Study reveals new findings of dietary changes within pancreatic cancer cells

    - PMLiVE

    Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

    Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

    - PMLiVE

    Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer

    The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links